Application of laser for treatment of cutaneous leishmaniasis: a review of literature

Cutaneous leishmaniasis (CL) is a major health problem in developing countries with high economic and health impact. Despite suggested treatment for CL, there is still no definite therapy for this infection, and many of these treatments are associated with serious local and systemic side effects. In the current paper, use of different laser types including continuous and fractional CO2, argon, PDL, erbium glass, and Nd:YAG have been reviewed. Based on our review, given the high reported efficacy and low side-effect profile, use of laser can be considered as a good alternative to standard treatment of cutaneous leishmaniasis (CL). Performing more studies using different types of lasers is recommended to evaluate the efficacy of this method for treatment of CL.

Paronychia-like cutaneous leishmaniasis

Chronic paronychia is an inflammatory recalcitrant disorder affecting the nail folds. We report one patient with paronychia revealing ungueal leishmaniasis. A 34-year-old man, resident in the north of Morocco, presented with a 6-month history of an inflamed proximal nail fold of the left thumb, resistant to antibiotics and anti-fungal treatments. En bloc excision of the proximal nail fold was done. The histopathological exam showed epithelioid granulomas with giant cells and the presence of leshmania amastigotes, leading to the diagnosis of ungueal leishmaniasis. Clinical aspects of cutaneous leishmaniasis can be very misleading. The paronychial form is rarely described. In endemic areas it is necessary for the physician to be aware of atypical skin presentations of leishmaniasis.

[Axillary hidrosadenitis due to Leishmania: Case report and literature review]

BACKGROUND

Hidradenitis is a disorder where abscesses appear after the infection of the apocrine sweat glands. It is located normally in the axillae, groin, perineal region, and the scalp.

CLINICAL CASE

A 37 year old male was referred by his GP to the General Surgery Department with axillary hidradenitis which had evolved over the years. The physical examination shows signs of hidradenitis in both axillae, with a noticeable suppurative hidradenitis in the right armpit. En bloc extirpation was performed to remove the whole affected area. The pathological examination revealed a cutaneous leishmaniasis. Subsequently, fucidin was administered topically, as well as local infiltrations of one millilitre of Glucantime™.

DISCUSSION

Hidradenitis normally appears in intertriginous areas and its manifestation is accompanied by recurrent subcutaneous nodules. The incidence rate in females is three times higher than in males. The isolated Hidradenitis caused by Leishmania is a rare condition presented only in endemic areas or in immunocompromised patients, such as HIV-infected patients. Clinical manifestations can be different and the diagnosis can be confirmed through haematoxylin-eosin. The main pattern displays a disorganised granuloma without necrosis. Systemic or topical treatment can be applied. Immunotherapy treatment is the most common.

CONCLUSIONS

Hidradenitis caused by Leishmania in HIV-negative patients is a rare condition. Therefore it is important to perform a good histological diagnosis and to administer the right treatment.

An unusual manifestation of a neglected disease

We report on a 30-year-old man that was seen by dermatologist for a routine check of melanocytic nevi. During the examination he pointed out a lesion on his upper back, stating that he did not know how long it had been there. Excision was performed and the histopathologic examination showed a dense granulomatous infiltrate in the dermis without ulceration. It turned out to be cutaneous leishmaniasis, the incidence of which is increasing in our immediate vicinity, and therefore it is important to constantly keep it in mind during everyday work at the clinic.

Leishmaniasis of the lip : report of a case

Leishmaniasis is a parasitic disease caused by a protozoan flagellate of the genus Leishmania. This parasite infects numerous mammal species including humans. It is transmitted through the infective bite of a sand fly called phlebotominae. Cutaneous Leishmaniasis is the most common form of Leishmaniasis. We present the case of a 47 years- old man who came to our Department of oral and maxillo-facial surgery, complaining about a painless lesion on his lower lip. After removal of the lesion and microscopic examination, the diagnosis of Leishmaniasis was made. This clinical case illustrates that the differential diagnosis of a nodular painless lesion of the lip must include rare diagnosis like a cutaneous Leishmaniasis, especially in patient from a geographic origin which represents an area at risk for Leishmaniasis.

Splenectomy does not interfere with immune response to Leishmania major infection in mice

Spleen is one of the largest lymphoid organs in the body; it harbors immune cells including antigen presenting cells, B and T lymphocytes. It has an important role in humoral and cellular immune responses. Herein we investigated the role of spleen in the immune response to experimental Leishmania major infection. It is known that C57BL/6 mice are resistant to L. major infection whereas BALB/c mice are susceptible. Although splenectomy was associated with reduced serum levels of IFN-gamma, absence of the spleen did not change the profile of L. major infection in the resistant C57BL/6 and BALB/c susceptible mice. Both strains of mice maintained the same profile of cytokine production in regional lymph nodes after splenectomy and responded in the same way against the infection. Only splenectomized BALB/c mice had a reduction in IL-4 and IL-10 production by lymph node cells early in infection. Our data suggest that, in localized infections, regional lymph nodes may replace efficiently the immunological role of spleen in the cellular and humoral immune responses.

Diagnosing cutaneous leishmaniasis: the advantage of forward deployed histology in avoiding a surgical pitfall

Military surgeons are often consulted for excisional debridement of skin lesions that fail to respond to medical therapy among soldiers who have been operating in areas of Afghanistan where cutaneous leishmaniasis is endemic. Wide surgical excision without knowledge of the primary etiology can lead to a surgical pitfall. Failure to properly treat cutaneous leishmaniasis, however, can lead to medical pitfalls of permanent disfigurement, deformity, and disability. Forward deployed surgeons should be supported by a laboratory that can confirm the presence of atypical organisms in biopsies of these lesions. With a x 100 microscope and Wright-Giemsa stains, a medical treatment facility is able to confirm cutaneous leishmaniasis, which allows for rapid transfer of soldiers for definitive antimicrobial therapy.

Carbon dioxide laser for the treatment of lupoid cutaneous leishmaniasis (LCL): a case series of 24 patients

We report the use of a carbon dioxide laser to vaporize local cutaneous leishmaniasis. We used CO2 laser for the treatment of 24 patients with lupoid cutaneous leishmaniasis in Isfahan. We identified 24 patients with lupoid cutaneous leishmaniasis (LCL) for evaluation. All of the patients had clinical signs of LCL and had the lesion for more than 1 year. LCL diagnosis was confirmed by both direct smear and biopsy. The efficacy of laser was determined on the basis of cure and lack of relapse after 1 year. Treatment was performed using a CO2 laser (Lasersonic LS500 machine). The maximum power was 100 Watts and the pulse width was 0.5-5 seconds. There were 21 patients, 13 females and 8 males, who were treated and followed for 1 year. Mean duration of the lesions was 4.1+/- 3.9 years. The treatment was well tolerated and complications were minimal, and included pain, xerosis, and mild erythema. Of these patients, 19 were disease free (90.47 % efficacy based on clinic and laboratory). Only 2 patients were treatment failures (9.5 %). Our results indicate that CO2 laser radiation is highly effective for treatment of lupoid cutaneous leishmaniasis.

Treatment of cutaneous leishmaniasis with cryosurgery

BACKGROUND

The management of cutaneous leishmaniasis with topical methods, if effective, can spare patients from long and costly inpatient treatments.

METHODS

Seventeen patients with cutaneous leishmaniasis were treated with cryosurgery using liquid nitrogen as the cryogen. Two cycles of 10-30 s freezing time were used and repeated at 3-week intervals.

RESULTS

All patients responded well to therapy with excellent cosmetic results and no relapse in any case. Side-effects were rare.

CONCLUSIONS

Cutaneous leishmaniasis can be successfully treated with a simple protocol of cryosurgery with minor side-effects.

Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis

BACKGROUND

Cutaneous leishmaniasis is a common disease in Iran, especially in the north-east, central and southern parts of the country. Many treatments have been suggested for this disease but none is completely effective and without side-effects such as pain, arthralgia and renal or cardiac complications. Lasers have been used for treatment of several skin diseases since 1970, and CO(2) lasers are now being used for treatment of leishmaniasis. In this study, a CO(2) laser (Sonic 500 machine) was used as a source of a continuous CO(2) laser wave.

METHODS

A total of 123 patients (68 female and 55 male) with 183 lesions were treated with the CO(2) laser. The maximum power was 100 W and the pulse width was 0.5-5 s. For the control group, 110 patients (with 250 lesions) were treated with glucantime 50 mg/kg/day for 15 days and, after 15 days of rest, this treatment was repeated (Glucantime Amps, 1.5 g in a 50-mL solution, was used). For follow-up, the patients were visited 1, 3, 4, 8, 12 and 24 weeks after treatment and any complications, recurrences or other wound characteristics were recorded. In the second group, Finally, all collected data were analyzed statistically.

RESULTS

Statistical analysis with the chi(2) test showed that treatment with the CO(2) laser was more effective than treatment with glucantime (P = 0.0007). Complications were also seen less often with the laser treatment than with glucantime and were limited to the ulcer site. The CO(2) laser was more effective in treating cutaneous leishmaniasis than glucantime (1.12 times), had fewer side-effects (4.5% vs. 24%) and resulted in a shorter healing time (1 month vs. 3 months), and treatment could be applied in a single session.

CONCLUSIONS

The results of this and previous studies suggest that cutaneous leishmaniasis can be treated effectively with CO(2) laser if those providing the treatment are sufficiently experienced. Laser treatment is more cost-effective than other treatments and can be used as first-line therapy for cutaneous leishmaniasis (wet and dry types).

CLINICAL FEATURES, EPIDEMIOLOGY, AND EFFICACY AND SAFETY OF INTRALESIONAL ANTIMONY TREATMENT OF CUTANEOUS LEISHMANIASIS: RECENT EXPERIENCE IN TURKEY

A total of 1,030 patients, 40.2% men and 59.8% women, identified during the period of October 1998 to November 2002 as having cutaneous leishmaniasis (CL), were studied; 1,431 lesions were identified in the 1,030 patients. One lesion was present in 80.7% of the patients. The size of the lesions (longest axis) was 13.6 mm (standard, 12.1 mm; range 3-150 mm). Most of the lesions were of the papular type (51.2%), although several atypical clinical presentations of CL were observed. The duration of the disease ranged between 1 and 72 mo (mean duration, 10.8 mo). The clinical suspicion of CL was confirmed by the observation of amastigotes on lesion tissue samples stained by Giemsa. The test was positive in 851 of 1,030 patients (82.6%). Intralesional meglumine antimonate solution (85 mg Sb/ml, 0.2-1 ml, depending on the size of the lesion) weekly until complete cure or up to 20 wk was used for first-line therapy of 890 patients (86.4%). We found that this regimen of intralesional Sb has an efficacy of 97.2% with a low relapse rate of 3.9% and no serious adverse side effects.

Treatment of cutaneous leishmaniasis among travellers

Leishmaniasis is endemic in 88 countries on five continents. There are 1-1.5 million cases of cutaneous leishmaniasis reported yearly worldwide. There has been a sharp increase in recorded cases over the last 10 years. Based on geographical distribution, cutaneous leishmaniasis is divided into Old World and New World leishmaniasis. In the past, species could be inferred from geographical setting or determined by performing culture and isoenzyme analysis. The recently developed and now widely available PCR technology allows a rapid diagnosis with determination of most species, and thus enables a species-orientated treatment. While the Old World species mostly cause benign and often self-limiting cutaneous disease, the American species cause a broad spectrum of conditions from benign to severe manifestations, including mucosal involvement. The response to treatment varies according to the species. Therefore, a species-specific approach is proposed. Drugs for systemic and topical treatment are presented and discussed with regard to their application, use and adverse effects. Indications for local or systemic treatment are proposed. Drugs under investigation are also mentioned. An overview of published treatment options and a treatment recommendation is given for each of the most important species. The level of evidence of the studies leading to these recommendations is given.

Juvenile acute cutaneous leishmaniasis: the first case report from north Scandinavia

A case of juvenile acute cutaneous leishmaniasis is reported. Treatment with freezing with CO2 snow was beneficial in healing of cutaneous lesions and no relapses have occurred.

A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis

BACKGROUND

Among the different modalities for treatment of cutaneous leishmaniasis, liquid nitrogen is considered an effective therapy with very mild side-effects.

METHODS

A study was conducted using liquid nitrogen topically for the treatment of cutaneous leishmaniasis in the King Hussain Medical Centre, Amman-Jordan. Among 468 patients of cutaneous leishmaniasis, 293 were treated with liquid nitrogen and the rest were treated with other known treatment modalities.

RESULTS

Of the patients treated with cryo surgery liquid nitrogen, 215 of 293 permitted appropriate follow-up; the clinical response was significant and effective. No systemic adverse effects were noted. Mild cutaneous complications were infrequent, and included hypopigmentation, hyperpigmentation, and scar formation.

CONCLUSIONS

From the results of this study, liquid nitrogen therapy may be considered an effective treatment for cutaneous leishmaniasis.

[Some aspects of work at the city laser surgery center of Ashgabad]

During 7-year work 2,500 operations with a laser were performed for 52 diseases at the center. The authors studied the medico-economical data on the use of the laser techniques in the treatment of persisting wounds and trophic ulcers, cutaneous leishmaniasis, chronic anal fissure, purulent diseases of the soft tissues, epithelial coccygeal passage, ingrowing nail, and localized hyperkeratosis. A comparison group consisted of patients who received traditional treatment. With the use of the laser methods the clinical results of treatment were appreciably improved--the number of poor results reduced, the duration of treatment was shorter, treatment in some cases could be changed from in-patient to out-patient, and a good cosmetic results with a marked economical effect was produced.

The clinical picture of six Egyptian cases of cutaneous leishmaniasis

Cutaneous leishmaniasis (CL) is a skin disease encountered in the East Mediterranean Region including Egypt. In this paper, it was intended to throw some light on the clinical picture of six parasitologically proven human CL. Also, the results of treating three cases of them with Pontostam or Cryosurgery. The whole results were discussed.